Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Organisation › Details

Immatics N.V. (Nasdaq: IMTX)

Period Start 2020-03-17 planned
  Group Immatics (Group)
Products Industry cancer drug
  Industry 2 ACTengine® cell therapy product
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Netherlands_oo
  Country Netherlands
  City n. a. 
    Address record changed: 2020-03-19
     
Basic data Employees D: 101 to 500 (2022-12-31)
  Currency EUR
  Annual sales 172,831,000 (revenue, consolidated (2022) 2022-12-31)
  Profit 37,514,000 (2022-12-31)
  Cash 148,519,000 (2022-12-31)
     
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top